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HSV regulatory proteins VP16 and ICP0 play key roles in launching the lytic program of viral gene expression in most cell types. However,
these activation functions are dispensable in U2OS osteosarcoma cells, suggesting that this cell line either expresses an endogenous activator of
HSV gene expression or lacks inhibitory mechanisms that are inactivated by VP16 and ICP0 in other cells. To distinguish between these
possibilities, we examined the phenotypes of somatic cell hybrids formed between U2OS cells and highly restrictive HEL fibroblasts. The U2OS-
HEL heterokarya were as non-permissive as HEL cells, a phenotype that could be overcome by providing either VP16 or ICP0 in trans. Our data
indicate that human fibroblasts contain one or more inhibitory factors that act within the nucleus to limit HSV gene expression and argue that
VP16 and ICP0 stimulate viral gene expression at least in part by counteracting this innate antiviral defence mechanism.
© 2006 Elsevier Inc. All rights reserved.Keywords: Herpes simplex virus; VP16; ICP0; Innate immunity; Somatic cell hybrid; Cell fusion; Reovirus p14Introduction
Innate immune defences protect eukaryotic organisms from
harmful invaders by coupling sensor-mediated recognition of
common pathogen-associated molecular patterns to potent and
specialized anti-pathogen responses (Kawai and Akira, 2005;
Netea et al., 2004). In the case of antiviral defence in
vertebrates, these responses include a variety of mechanisms
that act within infected cells to inhibit virus replication. Some of
these antiviral systems are broadly active, being able to inhibit
many viruses; examples include the type I interferon (IFN)
response and host apoptotic and RNA silencing pathways
(Benedict et al., 2002; Goodbourn et al., 2000; Voinnet, 2005).
Others, such as the retrovirus restriction factors APOBEC3G
and TRIM5α, are more selective and target only a subset of
viruses (Goff, 2004). Given the effectiveness of these varied
intracellular antiviral defences, it is not surprising that most if
not all viruses encode gene products that inactivate one or more
of these host systems (Benedict et al., 2002; Goodbourn et al.,⁎ Corresponding author. Fax: +1 780 492 9828.
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doi:10.1016/j.virol.2006.04.0212000; Voinnet, 2005). Indeed, mounting evidence documents
that the host range of many viruses is determined by the balance
between host innate defences and viral countermeasures
(Mariani et al., 2003; Stremlau et al., 2004; Wang et al., 2004).
An effective viral suppressor can mask the effects of an
otherwise potent cellular defence mechanism, hindering the
initial discovery of the antiviral mechanism. However, muta-
tions that inactivate the viral suppressor often give rise to a host
range phenotype such that the mutant virus is able to replicate
efficiently only in cells that lack the cognate host defence
mechanism (Chou et al., 1995; Mariani et al., 2003; Stremlau et
al., 2004; Wang et al., 2004). Such viral mutants and permissive
cell variants provide powerful tools for the discovery and
characterization of novel innate antiviral defence mechanisms.
In particular, somatic cell fusion experiments that probe the
basis for host range phenotypes have, in several cases, provided
the first evidence that the viral protein in question acts by
overcoming a cellular barrier to virus replication in restrictive
cells (Cowan et al., 2002; Madani and Kabat, 1998; Munk et al.,
2002; Simon et al., 1998). For example, HIV mutants lacking
the viral vif protein can be propagated in only a subset of T cell
lines in culture (Gabuzda et al., 1992; Strebel et al., 1987; von
Schwedler et al., 1993). Studies of somatic cell hybrids formed
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the non-permissive phenotype is dominant, implying that such
cells contain a trans-acting antiviral factor that is inactivated by
vif (Cowan et al., 2002; Simon et al., 1998). These findings set
the stage for the subtractive hybridization experiments that
identified the cellular cytosine deaminase APOBEC3G as the
antiviral factor targeted by vif (Sheehy et al., 2002).
In this report, we present the results of somatic cell fusion
experiments that probe the basis for the host range phenotype of
a herpes simplex virus type 1 (HSV-1) mutant that lacks
functional ICP0 and VP16, two proteins that stimulate viral
gene expression during the earliest stages of infection. As
elaborated below, our data argue that VP16 and ICP0 act at least
in part by overcoming one or more cellular barriers to viral gene
expression.
HSV-1 is a significant human pathogen and the prototypical
member of the herpesviridae, a family of large enveloped
nuclear DNA viruses. Depending on the nature of the host cell,
the virus either undergoes productive replication leading to cell
death or establishes a latent infection (reviewed in Roizman and
Knipe, 2001). The HSV lytic cycle involves the temporally
regulated expression of three sets of viral genes: immediate-
early (IE), early (E), and late (L). This genetic program is
initiated by the viral tegument protein VP16, which is released
into the cell following fusion of the viral envelope with the host
plasma membrane. VP16 binds the cellular factors HCF and
Oct-1 and the resulting tripartite complex then associates with
specific target sequences within the viral IE promoters (O'Hare
and Gooding, 1988; Preston et al., 1988; Stern et al., 1989; Xiao
and Capone, 1990). The C-terminus of VP16 serves as a strong
acidic transcriptional activation domain (Triezenberg et al.,
1988) that recruits factors involved in transcription initiation to
the viral IE promoters (Herrera and Triezenberg, 2004; Klemm
et al., 1995; Kobayashi et al., 1998; Memedula and Belmont,
2003; Mittler et al., 2003; Uesugi et al., 1997; Xiao et al., 1994).
VP16 stimulates the expression of five IE genes, four of which
encode proteins that collaborate to drive progression of the lytic
cycle into the E and L stages. One of these, ICP0, appears to act
upstream of the other IE proteins, as it is required along with
VP16 for efficient IE gene expression (Cai and Schaffer, 1992;
Cai et al., 1993; Everett et al., 2004a,b; Stow and Stow, 1986).
Thus, the functions of VP16 and ICP0 seem to be interrelated or
overlapping. Consistent with this view, ICP0 expressed in trans
can partially complement the transcriptional defect of VP16
mutants (Ace et al., 1989; Halford et al., 2001).
Viral mutants lacking the activation functions of ICP0 or
VP16 display a greatly increased particle-to-plaque forming
unit (PFU) ratio and substantially lower levels of IE gene
expression upon low multiplicity infection of many cell types
(Ace et al., 1989; Cai and Schaffer, 1992; Everett, 1989; Smiley
and Duncan, 1997; Stow and Stow, 1986). The severity of the
mutant phenotype varies between cell types, with primary
human fibroblasts being the most restrictive (Everett et al.,
2004a). In the absence of either or both of these proteins, the
viral genome often fails to engage the lytic program of gene
expression in restrictive cells and instead persists in a
transcriptionally silent, extrachromosomal state (Ace et al.,1989; Everett et al., 2004a; Harris and Preston, 1991; Harris et
al., 1989; Jamieson et al., 1995; Preston, 2000; Preston and
Nicholl, 1997; Russell et al., 1987; Samaniego et al., 1998;
Stow and Stow, 1986). Such quiescent genomes appear to be
actively repressed, as otherwise constitutively active heterolo-
gous promoters embedded within them are also silenced
(Jamieson et al., 1995; Minaker et al., 2005; Preston and
Nicholl, 1997; Samaniego et al., 1998). Thus, VP16 and ICP0
appear to modulate the fate of newly delivered viral genomes,
diverting them away from one or more cellular gene silencing
systems and towards a lytic infection.
ICP0 behaves as a promiscuous transactivator of viral and
cellular genes in transient cotransfection assays (Everett, 1985;
Gelman and Silverstein, 1985; O'Hare and Hayward, 1985;
Quinlan and Knipe, 1985), reviewed in Everett (2000), and it
stimulates expression of HSV genes belonging to all three
temporal classes during lytic infection (Cai and Schaffer, 1992;
Cai et al., 1993; Everett, 1989; Everett et al., 2004a; Jordan and
Schaffer, 1997; Samaniego et al., 1997; Stow and Stow, 1986).
A plausible hypothesis is that it stimulates viral gene expression
at least in part by counteracting the cellular silencing
mechanisms alluded to above (reviewed in Everett, 2000,
2006; Preston, 2000). Consistent with this hypothesis, ICP0
suffices to block entry into quiescence and is able to reactivate
silenced genomes (Harris and Preston, 1991; Harris et al., 1989;
Jamieson et al., 1995; Preston, 2000; Preston and Nicholl, 1997;
Samaniego et al., 1998; Stow and Stow, 1986). Little is known
about the mechanisms underlying silencing and reactivation of
quiescent HSV genomes; however, data obtained by Preston
and colleagues indicate that the newly delivered viral genome is
gradually assembled into a functionally inaccessible configura-
tion that precludes the action of many trans-acting factors,
including VP16 and the viral DNA replication machinery
(Preston and Nicholl, 1997); reviewed in Preston (2000). ICP0
is unique among HSV proteins in its ability to reactivate these
globally repressed genomes, and such genomes are neither
expressed nor replicated following productive superinfection
with ICP0-deficient HSV (Harris and Preston, 1991; Harris et
al., 1989; Hobbs et al., 2001; Minaker et al., 2005; Russell et al.,
1987). It is tempting to speculate that these anti-repression
activities of ICP0 also underlie its ability to promote efficient IE
gene expression during the earliest stages of a normal HSV
infection. However, the HSV IE promoters residing within
genomes destined for quiescence remain responsive to
transacting factors for at least 1 h after genome delivery, and
repression has been documented only after 24-h exposure to the
restrictive cellular environment in the absence of ICP0 (Preston
and Nicholl, 1997). Thus, it is currently unknown whether ICP0
stimulates gene expression at early times postinfection by
counteracting host inhibitory mechanisms.
ICP0 is an ubiquitin E3 ligase that interacts with a growing
list of cellular proteins, causing the degradation of some
(reviewed in Everett, 2000). Its E3 ligase function is essential
for transactivation and reactivation of quiescent viral genomes,
and these processes are blocked by proteasome inhibitors
(Boutell et al., 2002; Everett et al., 1995, 1998b; Hagglund et
al., 2002). These observations suggest that ICP0 may act by
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degradation. ICP0 is known to interact with type II histone
deacetylases (Lomonte et al., 2004) and components of the
CoREST/REST transcriptional repression complex (Gu et al.,
2005), suggesting a possible link with cellular repression
mechanisms and chromatin modifications. In addition, ICP0
causes the degradation of the histone variant CENP-A
(Lomonte et al., 2001), the centromeric protein CENP-C
(Everett et al., 1999) and the catalytic subunit of DNA-PK
(Lees-Miller et al., 1996; Parkinson et al., 1999), although the
functional significance of these findings remains unknown.
ICP0 also causes the degradation of several ND10 component
proteins, including the main structural protein PML (Chelbi-
Alix and de The, 1999; Everett and Maul, 1994; Everett et al.,
1998a). ND10 domains are distinct nuclear substructures that
appear to play roles in senescence (Pearson et al., 2000),
apoptosis (Hofmann and Will, 2003), DNA repair (Dellaire and
Bazett-Jones, 2004; Everett, 2006), signal transduction (Lin et
al., 2004) and viral replication (Maul, 1998; Nisole et al., 2005).
Interestingly, incoming HSV genomes induce de novo forma-
tion of adjacent nuclear ND10 bodies (Everett et al., 2004b),
and destruction of these domains has been correlated with ICP0
activation function (Everett and Maul, 1994; Everett et al.,
1998a). ICP0 is also critical for the resistance of HSV-1 to type I
interferon (IFN) (Eidson et al., 2002; Mossman et al., 2000;
Mossman and Smiley, 2002). Several ND10 components are
IFN-inducible (Gongora et al., 1997; Grotzinger et al., 1996;
Stadler et al., 1995), and the antiviral effect of IFN is abrogated
in PML−/− mouse embryo fibroblasts (Chee et al., 2003).
However, the precise roles of ND10 domains in modulating
HSV gene expression and ICP0 function are not fully
understood.
HSV-1 mutants lacking the activation functions of either
ICP0 or VP16 display a host range phenotype: they are
impaired for growth in primary human fibroblasts and many
established cell lines, but replicate efficiently in U2OS
osteosarcoma cells (Smiley and Duncan, 1997; Yao and
Schaffer, 1995). A viral mutant (KM110) that lacks both
functions displays a similar but greatly exaggerated phenotype,
being incapable of lytic growth or viral gene expression in
normal fibroblasts even after high multiplicity infection
(Mossman and Smiley, 1999). One possibility, originally
proposed by Yao and Schaffer (1995), is that U2OS cells
express a cellular factor that activates HSV-1 gene expression,
thus obviating the requirement for ICP0 and VP16 function;
another is that the permissive U2OS cells lack one or more
cellular antiviral mechanisms that are targeted by ICP0 and
VP16. In order to distinguish between these two possibilities,
we have performed somatic cell fusion assays similar to those
used to document the dominant blocks enforced by APO-
BEC3G and TRIM5α to retroviral replication (Cowan et al.,
2002; Madani and Kabat, 1998; Munk et al., 2002; Simon et al.,
1998). We found that heterokarya formed between permissive
and restrictive cells are completely non-permissive for KM110
IE gene expression, indicating that restrictive cells contain one
or more rapidly acting dominant inhibitory factors that are
absent from permissive U2OS cells. VP16 and ICP0 were eachable to override the non-permissive phenotype; in contrast, as
previously documented (Preston and Nicholl, 1997), only ICP0
was able to reactivate the viral genome following extended
exposure to the restrictive cellular environment. Our results
therefore document a dominant, innate, multi-step viral gene
silencing pathway which can be countermanded by either VP16
or ICP0 at early times postinfection.
Results
KM110 displays a strict host range phenotype
As reviewed in the Introduction, HSV-1 mutants lacking the
activation functions of VP16 or ICP0 often enter a transcrip-
tionally silent state following infection of restrictive cells such
as human embryonic lung (HEL) fibroblasts. The HSV-1 strain
KOS isolate KM110 lacks the activation functions of both VP16
and ICP0, and consequently displays a greatly exaggerated
phenotype relative to either singly mutant virus. KM110 does
not express its IE genes or replicate following high MOI
infection (10 PFU/cell) of HEL cells; the cells survive infection,
and the viral genome persists in a quiescent state for up to 10
days (Mossman and Smiley, 1999). In contrast, KM110 is able
to replicate to close to wild-type levels in permissive U2OS
osteosarcoma cells (Mossman and Smiley, 1999). To determine
if this striking host range phenotype can be readily visualized at
the level of individual cells in mixed cultures, the experiment
depicted in Fig. 1 was performed. HEL and U2OS cells were
stained red and blue respectively with the CellTracker probes
CMTMR and CMAC, then mixed together in a culture dish.
(Control experiments confirmed that these and other dyes used
in this study had no detectable effect on viral gene expression or
plaquing efficiency, data not shown). The mixed culture was
then infected with wild-type HSV-1 strain KOS (Figs. 1A and
B) or KM110 (Figs. 1C and D) at 10 PFU/cell. Nine hours later,
the cells were fixed and scored for expression of the viral IE
protein ICP4 by indirect immunofluorescence (IF) or viral DNA
replication by fluorescent in situ hybridization (DNA FISH)
using a probe spanning a large portion of the viral genome. Note
that the FISH assay was conducted under conditions that do not
detect unreplicated input viral genomes. As shown in Figs. 1A
and B, essentially every cell in the mixed culture was infected
by wild-type HSV-1, as evidenced by ICP4 protein production
and the formation of large intranuclear compartments contain-
ing replicated viral DNA (replication compartments). As
expected given the late time point analyzed, in most cells, the
ICP4 staining localized to large intranuclear structures shown
previously to correspond to replication compartments (Knipe et
al., 1987). In contrast, only the U2OS cells (blue) displayed
evidence of ICP4 protein production and viral genome
replication in the cultures infected with KM110: the HEL
cells (red) present in the same culture were uniformly negative
(Figs. 1C and D). These results confirm the strict host range
phenotype of KM110 and suggest that the single cell assays
used in this experiment are suitable for assessing the
permissivity of somatic cell hybrids formed between U2OS
and HEL cells.
Fig. 1. Host range phenotype of KM110. HEL cells (stained red with CMTMR) and U2OS cells (stained blue with CMAC) were mixed and infected with 10 PFU/cell
of wild-type HSV-1 KOS (A and B) or KM110 (C and D) for 9 h. Cells were then fixed and scored for ICP4 (A and C) or replicated viral genomes (B and D) via IF and
DNA-FISH respectively (green signals). Representative fields of view are shown. Scale bar = 10 μm.
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In order to determine whether hybrids of permissive and
non-permissive cells support or block the replication of
KM110, we developed a transient heterokaryon assay (out-
lined in Fig. 3 below). We elected to use the fusogenic
reovirus protein p14, a member of the fusion-associated small
transmembrane (FAST) protein family, as the fusion agent in
these experiments (Corcoran and Duncan, 2004). p14 is a
non-structural protein encoded by a reptilian reovirus thatpromotes cell–cell fusion, aiding rapid reovirus dissemination
(Corcoran and Duncan, 2004). Cells transfected with a p14
expression vector rapidly express p14 on their surface and
efficiently fuse with neighbouring non-expressing cells,
offering a simple and readily manipulated means of efficiently
creating somatic cell hybrids. However, as neither the
mechanism of p14-induced fusion nor its downstream effects
on other cellular processes are fully understood, we first
asked if p14-mediated cell–cell fusion alters the phenotypes
of U2OS or HEL cells with respect to the host range of
KM110.
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stained red with methyl bromide, and one culture was
transfected with a p14 expression plasmid; 6 h later, the
transfected cells were mixed with those of a parallel culture of
U2OS cells that had been infected with 10 PFU/cell KM110 1
h previously. The mixed culture was then incubated for 9 h, the
last seven of which were in the presence of a polyclonal rabbit
anti-p14 serum to slow the fusion process and prevent large
homokarya from forming. The cells were then fixed and scored
for ICP4 production by IF. ICP4 protein was observed in large
replication compartment structures in 14 of 14 homokarya
examined (for example, Fig. 2A) and in most unfused cells.
These data indicate that U2OS cells remain permissive to
KM110 following homotypic fusion.
A similar experiment was performed using HEL cells stained
green with CFMDA in order to determine whether fusion alters
their restrictive phenotype. Although the transfection efficiency
was much lower in these primary cells (ca. 5%), homokarya
could nevertheless be identified. KM110 failed to produce ICP4
in any of the five homokarya examined, suggesting that the
restrictive phenotype was maintained (Fig. 2B). To ensure that
these restrictive HEL homokarya contained KM110 genomes
that were potentially capable of gene expression, we cotrans-Fig. 2. Fusion does not affect the phenotype of U2OS or HEL cells. Homokarya fo
(B and C, stained green with CFMDA) were scored for their permissivity to KM
ICP0 expression vector pDR27 (C) were mixed 6 h posttransfection with a paral
Anti-p14 antiserum was added after 2 h, and cells were fixed and scored for
bar = 10 μm.fected a plasmid bearing an ICP0 cDNA driven from the
HCMV IE promoter along with the p14 expression plasmid into
HEL cells. When these cells were fused with HEL cells
previously infected with KM110, ICP4 replication compart-
ments were evident in ten of fourteen homokarya examined
(e.g., Fig. 2C). These results indicate that the p14-mediated
cell–cell fusion process does not alter the restrictive phenotype
of HEL cells with respect to KM110 replication and
demonstrate that ICP0 provided in trans is able to render HEL
cells permissive for KM110 IE gene expression.
Heterokarya formed between U2OS and HEL cells restrict
KM110 replication in the absence of viral activators
It has been suggested that U2OS cells express an ‘ICP0-like’
function that activates viral gene expression in the absence of
the transactivators VP16 and ICP0 (Yao and Schaffer, 1995);
alternatively, it is possible that these cells lack a cellular gene
silencing mechanism or other barrier to virus replication present
in restrictive HEL cells. Under the first scenario, heterokarya of
permissive U2OS and restrictive HEL cells are predicted to be
permissive for the replication of KM110, as the activating factor
contributed by the U2OS cells should be able to act upon thermed between U2OS cells (A, stained red with methyl bromide) or HEL cells
110. Cells transfected with pcDNA3-p14 (A and B) or pcDNA3-p14 and the
lel culture that had been infected with KM110 (10 PFU/cell) 1 h previously.
ICP0 via IF (blue) 7 h later. Representative homokarya are shown. Scale
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scenario predicts that the heterokarya would not support viral
replication, as the incoming genome would be silenced by the
repressive mechanism contributed by the HEL cells.
To distinguish between these possibilities, we used the p14-
mediated somatic cell fusion assay. A timeline of these
experiments is outlined in Fig. 3. U2OS cells were stained
blue with CMAC, then transfected with the p14 expression
plasmid. Five hours later, the cells were mixed with HEL cells
stained red with CMTMR that had been infected with 10 PFU/
cell KM110 1 h previously. (The HEL cells were washed with
an acid glycine solution prior to the addition of the U2OS cells
to remove any residual bound virus that had not yet penetrated
the plasma membrane). The mixed cultures were then incubated
for a total of 9 h in the presence of neutralizing human anti-HSV
serum. Anti-p14 antiserum was present during the last 7 h of
this incubation period, to slow the cell fusion process. The cells
were then fixed and scored for ICP4 expression and viral DNA
replication by IF and DNA FISH, as above. Note that in this
experimental design, the parental KM110 genomes were
delivered into the restrictive HEL cells prior to the introduction
of the U2OS cells.
Heterokarya were identified under the confocal microscope
as cells with multiple nuclei that fluoresced in both the red and
blue channels, indicating fusion between red HEL and blue
U2OS cells. In most experiments, both types of nuclei retained
their characteristic staining during the sample work-up,
allowing straightforward discrimination between the U2OS
and HEL nuclei present within individual heterokarya (see, for
example, Fig. 4). However, the blue CMAC stain was
occasionally lost from the U2OS nuclei during the DNA-
FISH procedure (for example, Figs. 6A and B); in such cases,
the HEL nuclei were readily identified on the basis of their red
staining, and the U2OS nuclei appeared as unstained areas in
both the blue and red channels. Using this procedure, we found
that the heterokarya formed between U2OS and HEL cells
failed to support viral IE protein production or KM110 genomeFig. 3. Experimental design.replication (Figs. 4A and C). All of the several hundred
heterokarya examined over the course of six independent
experiments were uniformly negative; twenty-six and fifteen
examples of these were photographed after staining for ICP4 or
viral DNA respectively. These observations suggest that U2OS
cells do not harbor a transacting factor capable of substituting
for VP16 and/or ICP0; rather the data imply that HEL cells
contain one or more dominantly acting negative factors that are
able to extinguish the permissive phenotype exhibited by U2OS
cells. In order to confirm that the KM110 genomes delivered to
the HEL cells prior to fusion with the U2OS cells were
potentially capable of undergoing replication in the presence of
transactivating proteins, in each of the six experiments
described above, some of the U2OS cells were cotransfected
with an ICP0 expression vector and the p14 expression plasmid.
When ICP0 was thus delivered into the infected HEL cells via
cell fusion, approximately 75% of the heterokarya examined
supported IE protein production and the infecting virus
underwent genome replication (twenty-eight and seventeen
examples of the heterokarya positive for ICP4 and viral DNA
respectively were photographed; Figs. 4B and D). Therefore,
ICP0 provided in trans is capable of activating a viral genome
residing in an otherwise restrictive heterokaryon.
Previous work by Preston and Nicholl has shown that the IE
promoters of HSV-1 genomes destined for quiescence are
initially delivered into cells in a form that is susceptible to trans-
activation by VP16 (Preston and Nicholl, 1997). In order to
determine if this is also the case in our system, we also tested the
ability of a VP16 expression plasmid to transactivate the viral
genome in three of the experiments described above (Fig. 5).
The results indicated that VP16 was also capable of activating
the newly delivered viral genome as evidenced by IE protein
production and viral genome replication in ca. 75% of the
heterokarya (eighteen and seven examples of these positive
heterokarya respectively were photographed; Figs. 5B and D).
Hence, VP16, like ICP0, can overcome the rapid, dominant
silencing mechanism that prevents IE gene expression in HEL
cells shortly after infection.
Evidence for rapid establishment of a restrictive nuclear
environment in heterokarya
An interesting observation made throughout the foregoing
experiments was that a strong viral DNA FISH signal was
detected in both the U2OS and HEL nuclei within heterokarya
when KM110 replication was triggered by ICP0 or VP16 (see
Figs. 4D and 5D). The finding that the replicated DNA signal
was present in both types of nuclei was at first glance surprising,
because the virus was initially delivered to the HEL cells prior
to fusion with the U2OS cells. The observation therefore raised
the possibility that not all of the input KM110 virions had
productively docked with or delivered their genomes into the
HEL cell nuclei prior to fusion with the U2OS cells, leaving
some virions free to deliver their genomes to the newly recruited
U2OS nuclei. Alternatively, and in our view much less likely,
the U2OS nuclei might have been infected by transfer of
un-encapsidated viral DNA between nuclei within the
Fig. 4. The restrictive phenotype of HEL cells is dominant in heterokarya. HEL cells (red) were infected with 10 PFU/cell of KM110, then fused with p14-expressing
U2OS cells (blue) 1 h later as outlined in Fig. 3. In panels B and D, the U2OS cells were transfected with the ICP0 expression vector pDR27 in addition to the p14
expression plasmid. Cells were fixed 9 h later and scored for ICP4 expression (A and B) and replicated viral DNA (C and D) by IF and DNA-FISH respectively (green
signals). Representative heterokarya are shown. Scale bar = 10 μm.
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another nucleus within the heterokaryon during viral egress.
To distinguish between these possibilities, we asked if the
incoming KM110 genomes became more strictly committed to
the HEL nuclei if the period between the initial infection and the
onset of fusion with the U2OS cells was increased from 1 h (as
in the preceding experiments) to 3, 12 and 48 h. As expected
according to the nuclear delivery model, when fusion with
U2OS cells expressing ICP0 was initiated 3 or more hours after
infection, the DNA FISH signal was detected in only the HELnuclei of the heterokarya (Figs. 6B and D, Fig. 7D, and data not
shown; note that the CMAC staining of the U2OS nuclei was
lost in the experiment depicted in Figs. 6A and B but retained in
the experiment shown in Figs. 6C and D). These results strongly
argue that nuclear genome delivery is complete within 3 h of
infection and imply that the DNA FISH signals within U2OS
nuclei observed in the 1 h experiments depicted in Figs. 4D, 5D,
6A and C arise from U2OS nuclei that were infected with input
KM1110 genomes shortly after the onset of cell fusion. If so,
then the finding that such infected U2OS nuclei fail to launch
Fig. 5. The KM110 genome responds to VP16 delivered in trans 1 h postinfection. HEL cells (red) were fused with U2OS cells (blue) 1 h after infection with
KM110, as in Fig. 4. In panels B and D, the U2OS cells were transfected with the VP16 expression vector pKOS-VP16 in addition to the p14 expression
plasmid. Cells were fixed 9 h later and scored for ICP4 expression (A and B) and replicated viral DNA (C and D) by IF and DNA-FISH respectively (green
signals). Representative heterokarya are shown. Scale bar = 10 μm.
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that the restrictive factors present in HEL cells rapidly render
newly recruited U2OS nuclei non-permissive for KM110
replication.
Loss of VP16 responsiveness at late times
The preceding data suggest that ICP0 and VP16 are both
capable of antagonizing the action of one or more dominant
inhibitory mechanisms that otherwise block viral IE geneexpression in restrictive HEL cells. The cellular inhibitory
mechanism(s) operate during the earliest stages of infection and
rapidly render U2OS nuclei non-permissive following cell
fusion. Preston and colleagues have shown that the viral IE
promoters gradually lose their ability to respond to VP16
provided in trans over the course of several days as HSV-1
genomes enter quiescence in restrictive cells (Preston and
Nicholl, 1997). Such genomes, however, continue to respond to
ICP0 even after responsiveness to VP16 has been lost (Preston
and Nicholl, 1997). The repression documented by Preston and
Fig. 6. Nuclear delivery of viral genomes is complete within 3 h. HEL cells (red) were mixed with U2OS cells (blue) expressing ICP0 and p14 at 1 (A and
C) or 3 (B and D) h after infection with KM110, essentially as outlined in Fig. 3. Cells were fixed 9 h after fusion and scored for replicated viral DNA
(green signal). The images shown in panels A and B were obtained in an experiment where the CMAC stain was lost from the U2OS nuclei; the images
shown in panels C and D are from a separate experiment where nuclear CMAC staining was retained. Representative heterokarya are shown. Scale
bar = 10 μm.
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detected in that repression was manifest only after 24 h, while
the dominant inhibition that we describe acts very rapidly. To
determine if the repressed state characteristic of genome
quiescence can be detected using our heterokaryon system,
we infected HEL cells with 10 PFU/cell of KM110 2 or 4 days
prior to fusion with p14-expressing U2OS cells. As expected
based on the preceding experiments, the quiescent viral genome
was not activated following fusion of the HEL cells with U2OS
cells in three independent experiments (Fig. 7, Fig. 8 and datanot shown). When ICP0 or VP16 were provided in trans, only
ICP0 was capable of reactivating the genome as evidenced by
ICP4 protein production and viral genome replication (compare
Figs. 7B and D to Figs. 8B and D). We note that reactivation
mediated by ICP0 occurred in a lower proportion of the
heterokarya (approximately 25%) than was observed when cell
fusion was initiated 1 h after infection (approximately 75%).
The basis for this difference in efficiency remains unclear.
These data confirm the observations of Preston and Nicholl
(1997) and suggest that HSV genome silencing is a multi-step
Fig. 7. Reactivation of the KM110 genome by ICP0 provided in trans 48 h postinfection. HEL cells (red) were infected with 10 PFU/cell of KM110, incubated 48 h,
then fused with p14-expressing U2OS cells (blue) as outlined in Fig. 3. In panels B and D, the U2OS cells were cotransfected with the ICP0 expression vector pDR27.
Cells were fixed 9 h later and scored for ICP4 expression (A and B) and replicated viral DNA (C and D) by IF and DNA-FISH respectively (green signals).
Representative heterokarya are shown. Scale bar = 10 μm.
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barriers to viral gene expression that can be overridden by either
VP16 or ICP0, followed by the slower establishment of a
globally repressed state that can be counteracted only by ICP0.
Discussion
Our data provide strong evidence that human fibroblasts
express one or more inhibitory factors that serve as an innate
barrier to the activity of incoming HSV genomes. We furthershow that the HSV regulatory proteins VP16 and ICP0, long
known to play key roles in launching the HSV lytic cycle,
stimulate viral gene expression at least in part by counteracting
this host inhibitory system. These studies were made possible
by the availability of three key biological reagents: a permissive
cell line, U2OS, in which HSV mutants lacking the activation
functions of ICP0 and/or VP16 replicate freely (Smiley and
Duncan, 1997; Yao and Schaffer, 1995); a viral VP16/ICP0
mutant, KM110, that is unable to replicate in other cell types
(Mossman and Smiley, 1999); and reovirus p14, a fusogenic
Fig. 8. VP16 is unable to reactivate KM110 at late times postinfection. HEL cells (red) were infected with 10 PFU/cell of KM110, incubated 48 h, then fused with p14-
expressing U2OS cells (blue) as in Fig. 7 and as outlined in Fig. 3. In panels B and D, the U2OS cells were cotransfected with the VP16 expression plasmid pKOS-
VP16. Cells were fixed 9 h later and scored for ICP4 expression (A and B) and replicated viral DNA (C and D) by IF and DNA-FISH respectively (green signals).
Representative heterokarya are shown. Scale bar = 10 μm.
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karya (Corcoran and Duncan, 2004). The exceptionally tight
host range phenotype of KM110 was an essential feature of our
experimental design, as it allowed us to load essentially every
cell in the culture with viral genomes via high MOI infection
without provoking detectable viral gene expression in the
restrictive HEL cells. Using these reagents, we show that the
permissive phenotype of U2OS cells is extinguished in somatic
cell hybrids formed with restrictive HEL fibroblasts, indicating
that U2OS cells lack the inhibitory mechanism that precludesreplication of KM110 in other cell types. The inhibitory
mechanism acts rapidly and in trans to prevent expression of
newly delivered viral genomes, as documented by the finding
that U2OS nuclei within heterokarya fail to support KM110
gene expression or replication, even when these nuclei are
seeded with viral genomes (Fig. 4, Fig. 5, Fig. 6). Inasmuch as
previous studies have shown that viral genomes enter the
nucleus in the absence VP16 or ICP0 function (Harris and
Preston, 1991; Jackson and DeLuca, 2003; Jamieson et al.,
1995), the simplest interpretation is that the inhibitory system
248 M.H. Hancock et al. / Virology 352 (2006) 237–252presents an intranuclear barrier to viral gene expression. Our
data therefore indicate that one or more factors contributed by
HEL cells are able to reconstitute an effective nuclear barrier in
U2OS nuclei. However, it is important to stress that this result
does not necessarily imply that the defect in U2OS cells resides
in the nuclear repression machinery per se. Indeed, the very
rapid induction of a restrictive intranuclear state following cell
fusion is consistent with the possibility that the U2OS cells
contain an intact nuclear repression machinery but lack a signal
transduction pathway required for its activity. Also consistent
with a signaling defect, reconstitution of the repression system
following cell fusion appears remarkably robust, as it is
insensitive to the relative contributions of HEL and U2OS
cells to individual heterokarya: heterokarya containing many
more U2OS than HEL nuclei remained completely non-
permissive (data not shown).
Previous genetic analysis has indicated that VP16 and ICP0
make largely independent contributions to triggering the onset
of the HSV lytic cycle, as the phenotype of the VP16/ICP0
mutant KM110 is much more severe than those of its singly
mutant parents in restrictive cells (Mossman and Smiley, 1999).
However, the finding that KM110 and its parents replicate
freely in U2OS cells suggests that the functions of VP16 and
ICP0 are somehow related. Consistent with this hypothesis, we
show here that the inhibitory mechanism present in HEL cells
imposes requirements for both viral proteins in heterokarya
formed with U2OS cells. Moreover, this barrier can be at least
partially overcome at early times by overexpressing either VP16
or ICP0. These findings lead us to propose that gene expression
is inhibited via a multi-step antiviral gene silencing pathway,
and that VP16 and ICP0 each serve as (incompletely effective)
inhibitors of separate steps in this pathway. We further suggest
that this gene silencing pathway is completely inactive in U2OS
cells, accounting for the ability of these cells to “complement”
defects in either or both viral functions. Although this model is
plausible and consistent with all of the available data, we cannot
at present exclude the alternative possibility that U2OS cells are
defective in two or more separate antiviral pathways, account-
ing for their ability to “complement” lesions in both VP16 and
ICP0.
Our finding that newly delivered HSV genomes are rapidly
subjected to negative regulation by the host cell is novel, as is
our evidence supporting roles for both VP16 and ICP0 in
countermanding this inhibition. As reviewed above, ICP0 is
able to reactivate repressed quiescent HSV genomes (Harris and
Preston, 1991; Harris et al., 1989; Hobbs et al., 2001; Minaker
et al., 2005; Preston, 2000; Preston and Nicholl, 1997; Russell
et al., 1987; Samaniego et al., 1998). We show here that ICP0
also acts at very early times postinfection to antagonize negative
regulation by the host cell, long before the stable repression
characteristic of quiescence has been established. These data
indicate that the early transactivation function of ICP0 is
accomplished, at least in part, by counteracting a constitutive
innate barrier to viral gene expression. Such an activity for ICP0
has long been suggested (Everett, 2000, 2001; Everett et al.,
1998b; Gu et al., 2005; Lomonte et al., 2004) but never directly
demonstrated. It will be interesting to learn whether and howthis activity relates to known biochemical activities of ICP0,
such as its ability to target host proteins such as PML for
degradation. A key question is whether early transactivation and
reactivation of quiescent viral genomes are accomplished by the
same mechanisms.
VP16 is often regarded as a direct activator of the HSV IE
genes, a role that is consistent with its ability to recruit
components of the transcription initiation complex such as RNA
polymerase II and TF IIB to viral IE promoters (Herrera and
Triezenberg, 2004). However, studies of the activity of the
VP16 activation domain in heterologous systems have revealed
that it also targets chromatin-remodeling coactivators and
adaptor proteins, including histone acetyltransferases (HATs)
and ATP-dependent chromatin-remodeling complexes (Klemm
et al., 1995; Kobayashi et al., 1998; Memedula and Belmont,
2003; Mittler et al., 2003; Uesugi et al., 1997; Xiao et al., 1994).
The interaction of VP16 with chromatin-remodeling proteins
was initially puzzling as the HSV genome was long thought to
be transcribed as naked DNA during lytic infection (Leinbach
and Summers, 1980; Muggeridge and Fraser, 1986). However,
recent evidence indicates that the newly delivered viral genome
rapidly associates with a limited number of nucleosomes, and
that the histones associated with specific viral genes display
activating modifications that change over time in response to
viral regulators in a fashion that reflects the sequential activation
of the IE, E and L genes during the lytic cascade (Herrera and
Triezenberg, 2004; Kent et al., 2004). These data suggest that
chromatin modifications might be a method of cellular control
of HSV gene expression. Consistent with this view, the C-
terminal activation domain of VP16 has recently been shown to
recruit HATs and ATP-dependent remodeling complexes to the
IE promoters during lytic infection of mammalian cells (Herrera
and Triezenberg, 2004). In addition, the activation domain
induced a specific deficit of histones over the IE promoters
(Herrera and Triezenberg, 2004). Thus, in addition to directly
activating gene expression, VP16 may also specifically prevent
repression mediated by inhibitory chromatin.
The foregoing considerations raise the possibility that the
host innate antiviral defence mechanism that we have
documented acts by detecting the incoming HSV genome
and then assembling it into repressive chromatin. Indeed, the
inhibitory pathway leads to the global repression characteristic
of genome quiescence, a state that is reminiscent of cellular
heterochromatin. This attractive and readily testable hypoth-
esis is consistent with many of the activities of ICP0 and
VP16 described above. If chromatin structure does in fact
underlie HSV genome repression, then it seems likely that a
specialized DNA replication-independent chromatin assembly
pathway (Loyola and Almouzni, 2004) such as that mediated
by the histone chaperone HIRA (Ray-Gallet et al., 2002) is
involved. It is interesting to note in this context that HIRA
associates with ND10 and has been linked to gene silencing
during cellular senescence (Zhang et al., 2005); moreover, it
functions in Drosophila to load histones onto the newly
delivered paternal genome immediately after fertilization
(Loppin et al., 2005), a situation perhaps analogous to
chromatinization of the incoming HSV genome. In view of
249M.H. Hancock et al. / Virology 352 (2006) 237–252the foregoing, we speculate that U2OS cells may be defective
in a signal transduction pathway that activates the nuclear
repression system in response to incoming HSV virions or
genomes or lack a specialized replication-independent chro-
matin assembly pathway and/or chromatin-dependent repres-
sion system.
Materials and methods
Cells and virus
Human U2OS osteosarcoma cells and human embryonic
lung (HEL) fibroblasts were obtained from the American Type
Culture Collection. Cells were maintained in Dulbecco's
modified Eagle medium (Gibco) supplemented with 10% fetal
bovine serum (FBS), 50 U/ml penicillin and 5 μg/ml
streptomycin. HEL cell cultures were additionally supplemen-
ted with 1 mM sodium pyruvate.
HSV-1 strain KOS was grown and titered on Vero cells,
while KM110 (Mossman and Smiley, 1999), a KOS derivative
lacking the activation functions of both VP16 and ICP0 was
grown and titered on U2OS cells in the presence of 3 mM
hexamethylene bis-acetamide (Sigma).
Cells were stained with various membrane permeable
fluorescent dyes in order to distinguish the cell types in the
somatic cell fusion assay. U2OS cells were stained with 15 μM
blue fluorescent 7-aminocoumarin (CMAC) or far red fluores-
cent BODIPY methyl bromide (Molecular Probes) and HEL
cells were stained with 10 μM orange fluorescent tetramethylr-
hodamine (CMTMR) or green fluorescent fluorescein diacetate
(CMFDA) (Molecular Probes) as described by the manufactur-
er. Control experiments confirmed that all four of these dyes had
no detectable effect on plaquing efficiency or expression of
ICP4 following infection of U2OS cells with wild-type HSV-1
KOS or KM110.
Cells were infected with 10 PFU/cell of the appropriate
virus, diluted in serum-free Dulbecco's modified Eagle
medium. Plates were rocked every 15 min for 1 h. In cell
fusion experiments, cells were then treated with acid glycine
to remove any input virus which had not penetrated the cell
surface: the monolayers were washed once with 1 ml
phosphate-buffered saline (PBS: 171 mM NaCl. 3.35 mM
KCl, 12.7 mM Na2HPO4, 1.72 mM KH2PO4, pH 7.5) then
incubated with 1 ml acid glycine (137 mM NaCl, 24.1 mM
KCl, 0.49 mM MgCl2 ˙6H20, 0.68 mM CaCl2 ˙6H20, 10 mM
glycine, pH 3) for 30 s. After two washes with 1 ml PBS,
growth medium containing 1% neutralizing human serum was
added to cells.
Plasmids and cosmids
A plasmid expressing the p14 fusion protein of reptilian
reovirus under the HCMV IE promoter (pcDNA3-p14) was a
generous gift from Dr Roy Duncan (Corcoran and Duncan,
2004). pDR27, a plasmid expressing a cDNA copy of ICP0
from an HCMV IE promoter, was a generous gift from Dr Peter
O’Hare. pKOS-VP16, containing the VP16 gene from HSV(strain KOS) under control of the VP16 promoter, was a
generous gift from Dr. Steven Weinheimer (Weinheimer et al.,
1992). A cosmid containing the HSV (strain 17) DNA fragment
with coordinates 79442–115152 cloned into the Pac1 sites of
SuperCos1 (cosmid 56) was a generous gift from Dr. Andrew
Davison (Cunningham and Davison, 1993).
Transient heterokaryon assay
U2OS cells were transfected with pcDNA3-p14 using
Lipofectamine 2000 (Invitrogen) according to the manufac-
turer's instructions. Transfection of HEL cells was carried out
using Exgen 500 (Fermentas) according to the manufacturer's
instructions. In some experiments, the ICP0 expression plasmid
(pDR27) or a VP16 expression plasmid (pKOS-VP16) was
cotransfected with the p14 expression plasmid.
Six hours after transfection (the point at which p14 is
beginning to be expressed on the cell surface), U2OS cells were
removed from their culture dishes using 10 mM EDTA in PBS.
The growth medium was aspirated, and cells were washed once
with 500 μl PBS. 500 μl 10 mM EDTA in PBS was added for
15 min. The 10 mM EDTA in PBS was removed, and cells
were resuspended in 500 μl PBS plus 100 μl FBS. Cells were
then centrifuged at 1750 rpm for 5 min, resuspended in 1 ml
growth medium and added to corresponding 12-well dishes or
chamber slides containing KM110-infected, adherent HEL
cells.
After 2 h of coculture, growth medium was aspirated from
cells and replaced with growth medium containing a 1:20
dilution of rabbit anti-p14 antiserum (a generous gift from Dr.
Roy Duncan) to inhibit the formation of large heterokarya. Cells
were left for a total of 9 h of infection before fixation.
Detection of ICP4 replication compartments via indirect
immunofluorescence
18-mm coverslips (Fisher Scientific) containing HEL:U2OS
heterokarya grown in 12-well plates were fixed by washing
once with 1 ml PBS and incubating in 500 μl PBS containing
5% formaldehyde and 2% sucrose for 10 min. Coverslips were
then washed once with PBS and incubated in 500 μl PBS
containing 0.5% Nonidet P-40 and 10% sucrose for 10 min.
After washing three more times with 1 ml PBS/1% FBS, the
cells were left for 1 h in PBS/1% FBS, then incubated with 50 μl
anti-ICP4 monoclonal antibody (#1114 Goodwin Institute)
diluted 1:1000 in PBS/1% FBS for 1 h. The coverslips were
further washed 3 times in PBS/1% FBS over a 15-min period
then incubated with 50 μl Alexa Fluor 488 labeled goat anti-
mouse IgG (Molecular Probes) diluted 1:1000 in PBS/1% FBS
for 1 h. Coverslips were again washed as above and dipped into
distilled water before being mounted onto slides using 25 μl
Vectashield (Vector Laboratories) and securing with clear nail
polish. Slides were examined using a Zeiss LSM 510 Confocal
Microscope using the lasers giving excitation lines at 488 (for
antibody staining), 546 (for CMTMR stained HEL cells) and
350 (for CMAC stained U2OS cells) and using a 40× oil
immersion objective lens.
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hybridization (FISH)
Heterokarya were formed in 4-well chamber slides (NUNC)
and fixed by washing once with 50 ml of PBS in a Coplin Jar,
then once with Cytoskeletal Buffer (CSK: 100 mM NaCl,
300 mM sucrose, 3 mMMgCl2, 10 mM PIPES pH 6.8) for 30 s,
CSK + 0.2% Tween-20 for 30 s, then again for 30 s with CSK.
4% paraformaldehyde was added to the Coplin Jar for 10 min.
Slides were stored in 70% ethanol at 4 °C until further use. Cells
were dehydrated in an ethanol series (70%, 85%, 95%, and
100%) for 2 min each, then incubated for 2 h at 37 °C with
50 μg/ml RNase A in a humid chamber. After this incubation,
the slides were washed 3 times for 5 min each at 39 °C with 2×
SSC (20× SSC: 3 M NaCl, 300 mM sodium citrate), then
underwent another ethanol dehydration series and were
incubated for 10 min at 70 °C in a 70% formamide/2× SSC
solution. The slides again underwent a dehydration series using
ice-cold ethanol and were completely dried before the
prehybridization step (see below for preparation of probe and
prehybridization mix). 3 μl of prehybridization probe was added
to the slides and spread under parafilm. The slides were
incubated for 1 h at 37 °C in a humid chamber, after which time
the parafilm was removed and 3 μl of labeled probe was added.
The slides were then incubated in the humid chamber at 37 °C
overnight. The next day, slides were washed twice at 39 °C in
1× SSC/50% formamide for 5 min each, once for 5 min at 39 °C
in 2× SSC and twice for 5 min at 39 °C in 1× SSC. 30 μl of
Fluorescein DCS (Vector Laboratories) diluted 1:50 in detection
buffer (1 part 20× SSC, 1part bovine serum albumin (10 mg/
ml), 3 parts H2O) was then added to slides and spread under
parafilm. The slides were incubated at 37 °C for 30 min in a
humid chamber, after which they were washed once in 4× SCC
at 39 °C for 5 min, once in 4× SSC/0.2% Tween-20 at 39 °C for
5 min, again in 4× SSC at 39 °C for 5 min and finally once in
distilled water at room temperature for 5 min. 70 μl of
Vectashield (Vector Laboratories) was placed on slides, and
coverslips were added and sealed with clear nail polish. Slides
were examined using a Zeiss LSM 510 Confocal Microscope
using the lasers giving excitation lines at 350 (for the CMAC-
stained U2OS cells), 488 (for the fluorescein-labeled probe) and
546 (for the CMTMR-stained HEL cells) and using a 40× oil
immersion objective lens.
Preparation of HSV DNA probe
The HSV DNA probe was made by removing the HSV-1
sequence with coordinates (79442–115152) from cosmid 56
using Pac1 restriction enzyme digestion and purification of the
ca. 35-kb fragment with an agarose gel DNA extraction kit
(Roche). The probe was biotin labeled using the BioPrime DNA
Labeling System (Invitrogen) according to the manufacturer's
instructions, purified on a Chroma Spin 100 column (Clone-
tech) and stored in 100% ethanol. Before use the probe was
combined with unlabeled human COT-1 DNA, salmon sperm
DNA, yeast tRNA and sodium acetate, precipitated and
resuspended in formamide. After incubation for 10 min at65 °C, the probe was mixed with 2× hybridization buffer (1 part
20× SSC, 2 parts bovine serum albumin (10 mg/ml), 2 parts
50% dextran sulphate), boiled for 5 min, cooled on ice and
incubated at 37 °C for 30 min before use. The prehybridization
mix was made as described above, while in the place of HSV
DNA, unlabeled cosmid 56 backbone derived from the initial
Pac1 digestion was added.
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